Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
IVERIC bio $160 million stock and warrants offering and private placement
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…
IDEAYA Biosciences $100 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA…
Constellation Pharmaceuticals $192.5 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the …
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Generation Bio $230 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering…
Applied Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics,…
ChemoCentryx $346.8 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5…
Jazz Pharmaceuticals $850 million exchangeable senior notes offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…